Your Messages Inbox
Your Article Summary
See Latest ArticlesXenoPort to Receive $23 Million in Milestone Payments Associated With FDA Acceptance of Solzira NDA
XenoPort, 03/17/09
XenoPort, Inc. announced that the U.S. Food and Drug Administration has accepted for review the new drug application filed by GlaxoSmithKline for Solzira Extended Release Tablets in the United States as a potential treatment for moderate-to-severe primary Restless Legs Syndrome. In accordance with XenoPort's collaboration agreements with GSK and Astellas Pharma Inc., the FDA's acceptance of the NDA triggers milestone payments to XenoPort of $23 million in the aggregate.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
US FDA approves SEROQUEL XR for add-on treatment of Major Depressive Disorder
AstraZeneca, 12/07/09
FDA Approves Initiation of Clinical Studies in the U.S. for T2000, Taros Proprietary Non-Sedating Barbiturate Compound
Taro Pharmaceuticals USA, 12/07/09
Article Search
Sponsor